Volume 2.46 | Dec 16

Prostate Cell News 2.46, December 16, 2011
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
Delivery of Multiple siRNAs Using Lipid-Coated PLGA Nanoparticles for Treatment of Prostate Cancer
Researchers report the fabrication of poly(lactic acid-co-glycolic acid) (PLGA)/siRNA nanoparticles coated with lipids for use as prostate cancer therapeutics made via a unique soft lithography particle molding process. [Nano Lett] Abstract

Free Nature Immunology Webcast: HIV Vaccines
PUBLICATIONS (Ranked by Impact Factor of the Journal)


Common Structural and Epigenetic Changes in the Genome of Castration Resistant Prostate Cancer
In this study, scientists investigated gene copy number and CpG methylation status in castration-resistant prostate cancer to gain insight into specific pathophysiological pathways that are active in this advanced form of prostate cancer. [Cancer Res] Abstract

Modeling Lethal Prostate Cancer Variant with Small Cell Carcinoma Features
Researchers developed a set of CRPC xenografts and examined their fidelity to their human tumors of origin. [Clin Cancer Res] Abstract

Differentiation of Prostate Cancer Cells by Using Flexible Fluorescent Polymers
By using a step-wise linear discriminant analysis, researchers demonstrate that the differential modulations of the polymer emission intensities in the presence of conditioned cell culture media can be used to distinguish between prostate cancer subtypes and between cancerous and non-cancer cells. [Anal Chem] Abstract

Effect of Dietary Polyunsaturated Fatty Acids on Castration-Resistant Pten-Null Prostate Cancer
In the present study, researchers sought to determine whether dietary polyunsaturated fatty acid affects the development of castration-resistant prostate cancer. [Carcinogenesis] Abstract

α-Mangostin, a Xanthone from Mangosteen Fruit, Promotes Cell Cycle Arrest in Prostate Cancer and Decreases Xenograft Tumor Growth
Researchers examined the anti-cancer effect of α-mangostin in human prostate cancer cells and its role in targeting cell cycle related proteins involved in prostate carcinogenesis. [Carcinogenesis] Abstract

Biochemical Relapse following Radical Prostatectomy and miR-200a Levels in Prostate Cancer
A pair of cancer and normal prostate cell lines derived from the same radical prostatectomy specimen were transfected with miR-200a to determine the effects on growth, wound healing, and invasion. [Prostate] Abstract

Double-Targeted and Double-Enhanced Suicide Gene Therapy Mediated by Generation 5 Polyamidoamine Dendrimers for Prostate Cancer
In this study, researchers established a novel system using nonviral gene vector generation 5 polyamidoamine dendrimer to express herpes simplex virus-thymidine kinase and connexin43 gene driven by prostate-specific membrane antigen promoter, and evaluated the anti-tumor effect of this system. [Mol Carcinog] Abstract

Human Prostate Cancer ZIP1/Zinc/Citrate Genetic/Metabolic Relationship in the TRAMP Prostate Cancer Animal Model
This is the first report that establishes the existence of the human prostate zinc/citrate hallmark characteristic and relationship in an animal model. [Cancer Biol Ther] Abstract


Identifying the Best Candidate for Radical Prostatectomy Among Patients with High-Risk Prostate Cancer
In this study, researchers’ objective was to identify which high-risk prostate cancer patients might have favorable pathologic outcomes when surgically treated. [Eur Urol] Abstract

180-W XPS GreenLight Laser Therapy for Benign Prostate Hyperplasia: Early Safety, Efficacy, and Perioperative Outcome After 201 Procedures
The objective of this study was to evaluate the prevalence of perioperative complications and short-term outcome for the first time with the XPS laser in men with lower urinary tract symptoms due to benign prostatic enlargement. [Eur Urol] Abstract

Early Changes in Apparent Diffusion Coefficient from Diffusion-Weighted MR Imaging During Radiotherapy for Prostate Cancer
The purpose of this study was to investigate the feasibility of diffusion-weighted MRI as an early and reproducible change indicator in patients receiving radiotherapy for prostate cancer. [Int J Radiat Oncol Biol Phys] Abstract

Association of 5α-Reductase Inhibitor Use and Pathological Features of Prostate Cancer in Men Undergoing Radical Prostatectomy
Researchers investigated the association of 5α-reductase inhibitor treatment with pathologic and biochemical outcome among the contemporary prostate cancer patients undergoing radical prostatectomy. [Prostate] Abstract

Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response


Nanostart-Holding MagForce Signs Letter of Intent with Leading Russian Medical Product Distribution Company Delrus
Nanostart-holding MagForce AG and Delrus Inc. announced the signing of a letter of intent (LOI) between the two companies. The LOI includes Delrus’ financial and professional support for the regulatory approval of NanoTherm therapy in brain tumors and other indications in Russia, including pancreatic and prostate cancer. [Business Wire] Press Release

CIRM Approves $27 Million for Initiatives to Accelerate Promising Stem Cell Research Projects
The California Institute for Regenerative Medicine (CIRM) enhanced its efforts to proactively discover and fund innovative research and to provide continuous support to successful research programs, speeding the development of new stem cell-based therapies. [California Institute for Regenerative Medicine] Press Release

Maryland Stem Cell Research Commission Issues Supplement to FY 2012 RFAs – Collaborative Research Opportunity with the California Institute for Regenerative Medicine
The Maryland Stem Cell Research Commission announced the second year of a pilot a program that provides an opportunity for collaboration with the California Institute for Regenerative Medicine. [The Maryland Stem Cell Research Fund] Press Release

Season's Greetings: Wishing You a Joyous Holiday Season and a Happy New Year

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW European Society for Radiotherapy & Oncology – World Congress of Brachytherapy
May 10-12, 2012
Barcelona, Spain

Visit our events page to see a complete list of events in the prostate cell community.

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientific Marketing Communications Specialist (STEMCELL Technologies Inc.)

Research Technologist, Manufacturing Sciences (STEMCELL Technologies)

Business Analyst – Product Management (STEMSOFT Software)

Research Associate – Development (Precision Therapeutics, Inc.) 

Postdoc – Prostate Cancer (Weill Cornell Medical College)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us